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To the Editor: Trimethoprim-sulphamethoxazole (TMP-SMX) is
highly effective for the prevention and treatment of
Pneumocystis carinii pneumonia (PCP). Paediatric HIV infection
is frequently complicated by PCP, a life-threatening,
opportunistic infection. At present, between 11% and 12% of
the South African population is infected with HIV-1. TMP-SMX
is an important disease-modifying antimicrobial preparation,
which reduces mortality and hospitalisation in HIV-infected
children significantly.
Since being introduced in the 1930s, the sulphonamides have
caused many adverse events. Before the HIV epidemic, less
than 4% of adults experienced adverse reactions after TMP-
SMX exposure. In contrast, approximately 60% of adults with
HIV infection may react adversely, with most reactions
consisting of mild drug eruptions. 1 There are few data on the
proportion of HIV-infected children who experience adverse
reactions to TMP-SMX therapy, but this is an uncommon
clinical problem at Red Cross Children’s Hospital (RXH).
Inducing tolerance after TMP-SMX reactions is both safe and
effective.2,3 We report the successful induction of tolerance after
a serious TMP-SMX reaction in an HIV-infected child.
A 9-month-old infant presented to RXH with severe
laryngotracheo-bronchitis and pneumonia. An emergency
intubation and subsequent tracheostomy were performed to
secure an adequate airway, and she required assisted
ventilation for hypoxaemia. She had generalised
lymphadenopathy, hepatosplenomegaly, and dermatitis,
features that are consistent with HIV infection, confirmed by
P24 antigenaemia. Severe immunosuppression (CD4 count
0.568 × 109/l, CD4 percentage 14%) and pancytopenia (white
cell count (WCC) 1.8 × 109/l, haemoglobin (Hb) 8.8 g/dl,
platelet count 50 × 109/l) were present. Although the chest
radiograph was not characteristic of PCP, an intravenous
loading dose of TMP-SMX was administered. This was
immediately followed by the development of generalised
urticaria and angio-oedema. The patient was
haemodynamically stable. Immunofluorescent stains were
negative for PCP. No further TMP-SMX was administered
during the first few days of hospitalisation.
On day 7 of the admission stavudine, lamivudine and
ritonavir were commenced. The pancytopenia had largely
resolved. Given the serious nature of the patient’s underlying
illness and the need for TMP-SMX prophylaxis, she was started
on an oral TMP-SMX tolerance induction regimen. The starting
daily dose was 1 ml (1:20 dilution of paediatric suspension),
which contained 0.4 mg TMP and 2 mg SMX, and this was
incrementally increased over 8 days when the recommended
maintenance prophylactic dose was reached, and subsequently
well tolerated (recommended prophylactic regimen in children:
150 mg TMP/m2/day with 750 mg SMX/m 2/day administered
either 3 times per week or 7 days per week). She recovered
from the acute illness and remains in a satisfactory condition
on antiretroviral therapy and TMP-SMX prophylaxis.
PCP causes considerable morbidity and mortality. The
explosive HIV epidemic in southern Africa has led to increased
use of TMP-SMX, the preparation of choice for both  PCP
prophylaxis and treatment. TMP-SMX is an inexpensive
formulation that is included in the South African Essential
Drugs List. In HIV-infected individuals, TMP-SMX also
prevents a spectrum of bacterial infections, toxoplasmosis and
isosporiasis.
Despite these therapeutic advantages, TMP-SMX may cause
serious adverse events, as this report illustrates. Alternative
drugs for preventing PCPinclude dapsone with or without
pyrimethamine, pentamidine, sulfadoxine plus pyrimethamine
and clindamycin plus primaquine.4 These agents present
variable challenges to paediatric practice including reduced
efficacy, complicated routes of administration, lack of
paediatric formulations, limited experience in children and
limited accessibility. They may also cause adverse reactions.
Anaphylaxis is a syndrome of varied clinical presentation
and severity. It is a potentially life-threatening event usually
mediated by an immunoglobulin E (IgE) immune reaction,
which is characterised by the sudden release of mast cell and
basophil mediators. Anaphylactoid reactions by contrast are
non-IgE-mediated events, which have a similar clinical
presentation to anaphylaxis, e.g. cytotoxic reactions resulting
from incompatible blood transfusions. There is no universally
acceptable definition of anaphylaxis. Diagnosis is largely based
on clinical considerations. The patient presented with features
consistent either with anaphylaxis or an anaphylactoid
reaction, urticaria and angio-oedema being common
manifestations of both conditions.5
Several immunological assays may be used to identify drug-
specific antibodies, drug-specific T-lymphocytes or mediators
elaborated by activated inflammatory cells. Tests available in
South Africa include skin prick tests, Immuno-CAP RAST
(Pharmacia, Uppsala, Sweden) and the CAST (Bühlmann,
Basel, Switzerland). As IgE-mediated mechanisms are not
always involved in drug reactions, negative results do not
necessarily exclude drug-induced hypersensitivity. Serum
tryptase (β-tryptase plus alpha-proto-tryptase) is concentrated
selectively in the granules of human mast cells, and correlates
with the clinical severity of anaphylaxis.6 If the clinical
presentation is equivocal, measuring serum tryptase may be
helpful in differentiating anaphylaxis from non-anaphylactic
358
Induction of tolerance after a serious trimethoprim-
sulphamethoxazole reaction in an HIV-infected child
SCIENTIFIC LETTERS
reactions, e.g. anaphylaxis versus acute severe asthma. Serum
tryptase cannot distinguish between an anaphylactic or
anaphylactoid reaction, as tryptase levels are elevated
regardless of the mechanism of mast cell activation. Tryptase
was not measured in the patient because there was a clear
causal relationship between TMP-SMX administration and the
development of symptoms. The tryptase assay is available at
the Allergology Unit, University of Cape Town.
Although tolerance can be induced in 33 - 100% of HIV-
infected individuals, neither the mechanism of TMP-SMX
hypersensitivity nor the immunological events underpinning
tolerance are understood.3 The term desensitisation implies that
the underlying mechanism is IgE-mediated. As the mechanism
of TMP-SMX hypersensitivity has not been fully elucidated, the
terms ‘graded challenge’, ‘test dosing’ or ‘tolerance induction’
are preferred in the context of a TMP-SMX reaction. 2 Common
features of TMP-SMX hypersensitivity such as erythematous or
maculopapular eruptions, leucopenia and fever suggest a cell-,
IgM- or IgG-mediated reaction. Evidence supporting the role of
IgE in the pathogenesis exists, i.e. skin prick and intradermal
skin test responses to sulphonamide determinants have been
documented in patients who have had adverse events.7 Non-
immune mechanisms may also contribute to TMP-SMX
reactivity.8 Additional factors that may predispose HIV-infected
individuals to TMP-SMX reactions include the slow acetylator
phenotype, high TMP-SMX dosages, severe immunosuppre s s i o n
and polypharmacy.9 It is likely that several mechanisms may
precipitate these reactions.
In conclusion, a number of approaches have been used to
induce tolerance. If PCPtherapy is urgently required, a 6-hour
graded TMP-SMX challenge may be used.3 Where minor
reactions have occurred, cautiously ‘treating through’ the event
will allow patients to tolerate TMP-SMX.2,10 When TMP-SMX
prophylaxis is needed a more gradual approach may be
adopted as demonstrated in this case. Induction of tolerance
should only be undertaken at institutions that have the
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To the Editor: The thalidomide tragedy is witness to the fact
that great care needs to be exercised in the administration of
drugs to pregnant women. Approximately 80% of Zulu and
Xhosa women in South Africa use traditional medications
during pregnancy, so a knowledge of the toxicity of plants
commonly chosen by traditional healers for pregnant women is
of vital importance in assessing the potential impact they might
have on the health of both the mother and the developing fetus.
The primary function of isihlambezo is to ensure adequate
fetal growth and wellbeing and to promote general maternal
health and a quick uncomplicated labour. However, there have
been reports raising concern about the toxicity of some of the
approximately 60 plant species used in isihlambezo mixtures.
Rhoicissus tridentata extracts have been linked to a number of
fatalities caused by central nervous system (CNS) depression
and respiratory failure.1,2 Animal deaths3 have also been
attributed to this species. Although the fruits of the genus
Combretum are widely regarded as toxic, and are not consumed
by wild animals or used by healers,4 there is only one case in
which the toxicity of the fruit has been clinically proven.4 In
1996 it was reported that 5 women in Zimbabwe died after
vaginal insertion of material from Combretum erythrophyllum,
from the same genus of the Combretaceae family as C. kraussii.4
The butanol extract from C. kraussii was found to be toxic to
brine shrimp.4 However the organic solvent butanol is not used
by healers, who extract plants with boiling water. The toxicity
of several other species has also been reported. 5
We carried out a study in order to establish whether Gunnera
perpensa (uqobo in Zulu), C. kraussii Hochst (umdubu in Zulu)
and R. tridentata subsp. cuneifolia (isinwazi in Zulu), exhibited
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